Indications : התוויות

4.1   Therapeutic indications

Tritherapy
PegIntron in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy (see section 5.1).
Please refer to the ribavirin and boceprevir Physician's Insert when PegIntron is to be used in combination with these medicines.
Bitherapy and monotherapy
PegIntron is indicated for the treatment of adult patients (18 years of age and older) with chronic hepatitis C (CHC) who have elevated transaminases without liver decompensation and who are positive for serum hepatitis C virus RNA (HCV-RNA) or anti-HCV, including naïve patients with clinically stable HIV co- infection (see section 4.4).

PegIntron in combination with ribavirin (bitherapy) is indicated for the treatment of chronic hepatitis C (CHC) infection in patients who are previously untreated including patients with clinically stable HIV co- infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy (see section 5.1).

Interferon monotherapy, including PegIntron, is indicated mainly in case of intolerance or contraindication to ribavirin.

Please refer to the ribavirin Physician's Insert when PegIntron is to be used in combination with ribavirin.